Why the study?
Interpatient variability and resistance to clopidogrel have prompted the investigation of novel antiplatelet agents, such as prasugrel and other nonthienopyridine derivatives, that meet pharmacokinetic demands while maintaining a satisfactory safety profile.
Does prasugrel reduce ischemic endpoints (myocardial infarction, thromboocclusive episodes, and death) compared to standard antiplatelet therapy in patients with coronary artery disease?
Does prasugrel reduce ischemic endpoints (myocardial infarction, thromboocclusive episodes, and death) compared to standard antiplatelet therapy in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
Novel antiplatelet agents like prasugrel address clopidogrel resistance and variability by significantly reducing ischemic endpoints including myocardial infarction and death in coronary artery disease.
The role of antiplatelet therapy in the management of coronary artery disease and its sequalae is of great significance. Acetil Salycilic Acid (ASA) has continued to dominate the field as a potent antiplatelet agent, due to its ease of use and cost effectiveness. In addition to this, clopidogrel has also been widely used with better long term administration results in patients with atherosclerotic disease. However, interpatient variability and resistance to clopidogrel has opened the doors for further investigative research to find another agent which potentially meets the pharmacokinetic demands whilst having a satisfactory safety profile. Prasugrel and other novel nonthienopyridine derivatives are currently under investigation, with previous trials showing very reassuring outcomes. Patented inventions along with large trials have shown that prasugrel significantly reduces ischemic end points, ultimately resulting in a decrease in Myocardial infarctions, thromboocculusive episodes and death. Further studies are required to support these findings before we are aware of all clinical effects of Prasugrel.
No takes yet. Share an insight, caveat, or question.
Postula et al. (2009) conducted a review in Coronary artery disease and atherosclerotic disease. Prasugrel and novel nonthienopyridine antiplatelet agents vs. Acetylsalicylic acid (ASA) and clopidogrel was evaluated on Ischemic endpoints (myocardial infarctions, thromboocclusive episodes, and death).
Synapse has enriched 10 related papers. Consider them for comparative context: